Carrier Screening Market by Type (Expanded Carrier Screening, Targeted Disease Carrier Screening), Medical Condition (Hematological Conditions, Neurological Conditions, Pulmonary Conditions), Technology, End-User - Global Forecast 2024-2030

Carrier Screening Market by Type (Expanded Carrier Screening, Targeted Disease Carrier Screening), Medical Condition (Hematological Conditions, Neurological Conditions, Pulmonary Conditions), Technology, End-User - Global Forecast 2024-2030

The Carrier Screening Market size was estimated at USD 3.07 billion in 2023 and expected to reach USD 3.52 billion in 2024, at a CAGR 14.93% to reach USD 8.13 billion by 2030.

Carrier screening is genetic testing conducted on individuals to determine whether they carry a gene for certain genetic disorders. As carriers, these individuals typically do not exhibit symptoms of the disorder; however, they can pass the gene on to their offspring, who may be at risk of inheriting the disease. Carrier screening is particularly recommended for individuals with a family history of genetic disorders or for those within certain ethnic groups that have a higher prevalence of specific genetic conditions. The increasing prevalence of inherited diseases, growing awareness among potential parents, and supportive government policies aimed at reducing the burden of genetic disorders increase the adoption of carrier screening. However, concerns associated with genetic data, the complexity of genetic counseling, and occasional false positives/negatives could lead to cumbersome follow-up testing and impending market growth. Nevertheless, the integration of next-generation sequencing (NGS) technologies, which allow for comprehensive screening of a large number of genetic conditions at once, the potential for growth in direct-to-consumer genetic testing services, and the expansion of carrier screening programs at the population level in various countries are expected to create potential opportunities for the market growth.

Regional Insights

The Americas have a mature market for carrier screening, owing to heightened awareness, technological advancements, and the presence of key market players. In the United States, there is a considerable consumer need for carrier screening due to the diverse genetic makeup of the population and increasing healthcare expenditure. The Affordable Care Act has also impacted the market positively by enabling a broader population to access such screenings. Physician recommendations and the availability of direct-to-consumer genetic testing services influence customer purchasing behavior in these regions. Key patents include advances in sequencing technologies and bioinformatics algorithms for detecting genetic variants. The European market is characterized by consumer needs and purchasing behavior across EU countries, shaped by cultural perspectives, healthcare policies, and genetic counseling practices. Nations with more robust healthcare infrastructure and higher per capita income, such as the Scandinavian countries, exhibit higher adoption rates of carrier screening. Initiatives, including the Horizon Europe program, support research and innovation in the field while GDPR legislates genetic data management. Recent investments are seen in public-private partnerships aimed at enhancing genetic testing technologies. The Middle East is experiencing an increase in demand for carrier screening due to high consanguinity rates, leading to a greater prevalence of genetic disorders. Countries in the Middle East are investing in population-scale genetic projects to improve public health. In Asia-Pacific, carrier screening markets are experiencing rapid growth due to increased investment in healthcare infrastructure. Government initiatives such as the Healthy China 2030 blueprint and the Genome Japan project reflect the country's commitment to advancing genomic medicine. Countries in Asia-Pacific present a vast opportunity, with a burgeoning middle class and increasing healthcare awareness. Patents in the Asia Pacific region are focusing on new genetic technologies and cost-effective testing methods to cater to the growing market. Overall, the region presents a significant potential for growth and innovation in carrier screening.

Market Insights

Market Dynamics

The market dynamics represent an ever-changing landscape of the Carrier Screening Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.

Market Drivers

• Growing prevalence of inherited diseases and focus on early disease detection and prevention
• Rising geriatric population and high risk of chromosomal abnormalities
• Increasing investment in healthcare infrastructure and government initiatives for the management of genetic disorders

Market Restraints

• Dearth of skilled professionals and professional services

Market Opportunities

• Emerging improvements in POC diagnostics
• Technological advancements in carrier screening

Market Challenges

• Presence of non-uniform standards and guidelines

Market Segmentation Analysis

• Type: Expanded carrier screening (ECS) offers a wide overview of genetic health and conditions
• End-User: Evolving application of carrier screening in hospitals

Market Disruption Analysis

• Porter’s Five Forces Analysis
• Value Chain & Critical Path Analysis
• Pricing Analysis
• Technology Analysis
• Patent Analysis
• Trade Analysis
• Regulatory Framework Analysis

FPNV Positioning Matrix

The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Carrier Screening Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Carrier Screening Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Recent Developments

Invitae Completes Sale of Reproductive Health Assets to Natera

Invitae Corporation divested certain reproductive health assets to Natera Inc. in a deal valued at up to USD 52.5 million, including cash, milestone payments, and litigation credits. Under this agreement, Invitae's carrier screening and non-invasive prenatal screening endeavors and the associated customer base are set to be transferred to Natera.

Fulgent Genetics Launches New Beacon787 Expanded Carrier Screening Panel

Fulgent Genetics, Inc. unveiled its latest innovation, the Beacon787 carrier screening panel, with the broadest gene coverage, including 787 autosomal recessive and X-linked conditions. This screening is especially pivotal for pregnant individuals or those planning for pregnancy, aiming to uncover genetic risks that might not be evident due to lack of symptoms or family history.

Bio-Techne and Oxford Nanopore Technologies Partner to Bring Innovative Reproductive Health and Carrier Screening Solutions to the Market

Asuragen, Inc., a subdivision of Bio-Techne Corporation, and Oxford Nanopore Technologies PLC joined forces to revolutionize carrier screening in reproductive health. This groundbreaking collaboration aims to develop assays that integrate Asuragen's exceptional long-range PCR technology with the unique any-read-length sequencing capability of Oxford Nanopore.

Strategy Analysis & Recommendation

The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Carrier Screening Market. This critical assessment involves a thorough analysis of the organization’s resources, capabilities, and overall performance to identify its core strengths and areas for improvement.

Key Company Profiles

The report delves into recent significant developments in the Carrier Screening Market, highlighting leading vendors and their innovative profiles. These include 23Andme Inc., Abbott Laboratories, Ambry Genetics Corporation by Konica Minolta, Inc., Asper Biogene, Autogenomics Inc. by Prescient Medicine Holdings Inc., BGI Genomics Co., Ltd., Biora Therapeutics, Inc., CENTOGENE N.V., Danaher Corporation, Eurofins Scientific, F. Hoffmann-La Roche Ltd., Fulgent Genetics, Inc., Gene by Gene, Ltd. by myDNA Inc., GeneDx Holdings Corp., Illumina Inc., Invitae Corporation, Laboratory Corporation of America Holdings, Luminex Corporation by DiaSorin Company, MedGenome Labs Ltd., Myriad Genetics, Inc., Natera, Inc., OPKO Health, Inc., Otogenetics Corporation, Quest Diagnostics Inc., Thermo Fisher Scientific Inc., and TRUE HEALTH LABS.

Market Segmentation & Coverage

This research report categorizes the Carrier Screening Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Type
• Expanded Carrier Screening
• Customized Panel Testing
• Predesigned Panel Testing
• Targeted Disease Carrier Screening
• Medical Condition
• Hematological Conditions
• Neurological Conditions
• Pulmonary Conditions
• Technology
• DNA Sequencing
• Microarrays
• Polymerase Chain Reaction
• End-User
• Hospitals
• Physician Offices & Clinics
• Reference Laboratories

Region

• Americas
• Argentina
• Brazil
• Canada
• Mexico
• United States
• California
• Florida
• Illinois
• New York
• Ohio
• Pennsylvania
• Texas
• Asia-Pacific
• Australia
• China
• India
• Indonesia
• Japan
• Malaysia
• Philippines
• Singapore
• South Korea
• Taiwan
• Thailand
• Vietnam
• Europe, Middle East & Africa
• Denmark
• Egypt
• Finland
• France
• Germany
• Israel
• Italy
• Netherlands
• Nigeria
• Norway
• Poland
• Qatar
• Russia
• Saudi Arabia
• South Africa
• Spain
• Sweden
• Switzerland
• Turkey
• United Arab Emirates
• United Kingdom

Please Note: PDF & Excel + Online Access - 1 Year